A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018/PNEU-WAY)

Inclusion Criteria:

- Male or female infected with human immunodeficiency virus (HIV) and Cluster of
Differentiation 4+ (CD4+) cell count ≥50 cells/µL and plasma HIV ribonucleic acid
(RNA) <50,000 copies/mL

- Receiving combination anti-retroviral therapy (ART) for at least 6 weeks before
enrollment with no intention of changing therapy for 3 months after randomization

- Female participant: not pregnant, not breastfeeding and 1) not of childbearing
potential, or 2) of childbearing potential and agrees to practice contraception
through 6 weeks after administration of study vaccine.

Exclusion Criteria:

- History of opportunistic infections within 12 months before the first study
vaccination

- History of non-infectious acquired immune deficiency syndrome-related illness such as
Kaposi's sarcoma, wasting syndrome, or HIV-associated nephropathy

- History of invasive pneumococcal disease

- Known hypersensitivity to any vaccine component

- Known or suspected congenital immunodeficiency, functional or anatomic asplenia, or
history of autoimmune disease

- Coagulation disorder contraindicating intramuscular vaccination

- History of malignancy ≤5 years before enrollment, except for adequately treated basal
cell or squamous cell skin cancer or in situ cervical cancer

- Female participant: positive urine or serum pregnancy test

- Prior administration of any pneumococcal vaccine

- Received systemic corticosteroids for ≥14 consecutive days and have not completed
within 30 days of enrollment

- Received immunosuppressive therapy

- Received a blood transfusion or blood products within 6 months of enrollment

- Participated in another clinical study of an investigational product within 2 months
of enrollment

- Current user of recreational or illicit drugs or history of drug or alcohol abuse or
dependence.